ESPR
Price
$2.10
Change
-$0.13 (-5.83%)
Updated
Nov 14 closing price
104 days until earnings call
SCYX
Price
$1.26
Change
-$0.03 (-2.33%)
Updated
Nov 14 closing price
131 days until earnings call
Ad is loading...

ESPR vs SCYX

Header iconESPR vs SCYX Comparison
Open Charts ESPR vs SCYXBanner chart's image
Esperion Therapeutics
Price$2.10
Change-$0.13 (-5.83%)
Volume$4.21M
CapitalizationN/A
SCYNEXIS
Price$1.26
Change-$0.03 (-2.33%)
Volume$211.72K
CapitalizationN/A
ESPR vs SCYX Comparison Chart
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ESPR vs. SCYX commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a Hold and SCYX is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (ESPR: $2.10 vs. SCYX: $1.26)
Brand notoriety: ESPR and SCYX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ESPR: 111% vs. SCYX: 148%
Market capitalization -- ESPR: $495.94M vs. SCYX: $55.88M
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. SCYX’s [@Pharmaceuticals: Other] market capitalization is $55.88M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 1 FA rating(s) are green whileSCYX’s FA Score has 1 green FA rating(s).

  • ESPR’s FA Score: 1 green, 4 red.
  • SCYX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ESPR and SCYX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 4 TA indicator(s) are bullish while SCYX’s TA Score has 3 bullish TA indicator(s).

  • ESPR’s TA Score: 4 bullish, 4 bearish.
  • SCYX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than SCYX.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а -0.47% price change this week, while SCYX (@Pharmaceuticals: Other) price change was -5.26% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +56.20%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -6.95%.

Reported Earning Dates

ESPR is expected to report earnings on Feb 27, 2025.

SCYX is expected to report earnings on Mar 26, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+56.20% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESPR($496M) has a higher market cap than SCYX($55.9M). ESPR YTD gains are higher at: -29.766 vs. SCYX (-43.498). SCYX has higher annual earnings (EBITDA): 70.9M vs. ESPR (-150.11M). ESPR has more cash in the bank: 82.2M vs. SCYX (74.4M). SCYX has less debt than ESPR: SCYX (15.1M) vs ESPR (266M). SCYX has higher revenues than ESPR: SCYX (140M) vs ESPR (116M).
ESPRSCYXESPR / SCYX
Capitalization496M55.9M887%
EBITDA-150.11M70.9M-212%
Gain YTD-29.766-43.49868%
P/E RatioN/A1.06-
Revenue116M140M83%
Total Cash82.2M74.4M110%
Total Debt266M15.1M1,762%
FUNDAMENTALS RATINGS
ESPR vs SCYX: Fundamental Ratings
ESPR
SCYX
OUTLOOK RATING
1..100
7954
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
4189
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (32) in the Biotechnology industry is in the same range as SCYX (42) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to SCYX’s over the last 12 months.

ESPR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SCYX (100) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to SCYX’s over the last 12 months.

SCYX's SMR Rating (12) in the Pharmaceuticals Other industry is significantly better than the same rating for ESPR (100) in the Biotechnology industry. This means that SCYX’s stock grew significantly faster than ESPR’s over the last 12 months.

ESPR's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for SCYX (89) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew somewhat faster than SCYX’s over the last 12 months.

SCYX's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that SCYX’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRSCYX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SCYX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and ORGO have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and ORGO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-5.83%
ORGO - ESPR
32%
Poorly correlated
-9.59%
CTLT - ESPR
31%
Poorly correlated
-0.41%
SCYX - ESPR
29%
Poorly correlated
-2.33%
EVO - ESPR
26%
Poorly correlated
+12.09%
PAHC - ESPR
25%
Poorly correlated
-1.46%
More

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and ESPR have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ESPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
-2.33%
ESPR - SCYX
26%
Poorly correlated
-5.83%
ORGO - SCYX
26%
Poorly correlated
-9.59%
AMPH - SCYX
24%
Poorly correlated
-0.92%
CURLF - SCYX
23%
Poorly correlated
-1.79%
HNSPF - SCYX
22%
Poorly correlated
N/A
More